Literature DB >> 9219728

Regulation of MMP-9 (92 kDa type IV collagenase/gelatinase B) expression in stromal cells of human giant cell tumor of bone.

V H Rao1, R K Singh, J A Bridge, J R Neff, G B Schaefer, D C Delimont, C M Dunn, W G Sanger, B A Buehler, R Sawaya, G L Nicolson, J S Rao.   

Abstract

Matrix metalloproteinases (MMPs) play an important regulatory role in tissue morphogenesis, cell differentiation, tumor invasion and metastasis. Several authors have reported a direct correlation between the production of 72 kDa (MMP-2) and 92 kDa (MMP-9) type IV collagenases/gelatinases and the metastatic potential of cancer cells. Recently, we have identified the expression of both MMP-2 and MMP-9 in primary cultures of human giant cell tumor (GCT) of bone in vitro, and in tissue extracts in vivo. Interestingly, MMP-9 is not secreted by late-passaged GCT cells. It is possible that the production of MMP-9 is regulated by certain factor(s) secreted by the multinucleated giant cells in the primary culture. In order to test this hypothesis, the effect of primary-culture-conditioned medium on the expression of MMP-9 by late-passaged mononuclear stromal cells was examined. Adding conditioned medium from the primary GCT culture to the late-passaged stromal cells induced MMP-9, as evidenced by the presence of lytic bands at M(r) 92,000 and 72,000 on a gelatin zymogram. These enzyme activities were inhibited by EDTA, a well-known inhibitor of the MMPs. We confirmed these results by Western blotting using specific antibodies and RT-PCR for MMP-2 and MMP-9. Immunofluorescence studies with specific antibodies to MMP-9 further confirmed its expression by the passaged stromal cells cultured in the primary-culture-conditioned medium. The data indicate that MMP-2 and MMP-9 are produced by the mononuclear stromal cells when cultured in GCT primary-culture-conditioned medium. This suggests that multinucleated giant cells in primary cultures secrete a factor(s) that stimulates stromal cells to produce MMP-9, which, in turn, may contribute to the aggressive behavior of GCT.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219728     DOI: 10.1023/a:1018450204980

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  41 in total

1.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials.

Authors:  M Nakajima; D R Welch; P N Belloni; G L Nicolson
Journal:  Cancer Res       Date:  1987-09-15       Impact factor: 12.701

2.  Degradation of basement membranes by human matrix metalloproteinase 3 (stromelysin).

Authors:  P A Bejarano; M E Noelken; K Suzuki; B G Hudson; H Nagase
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

Review 3.  Characterization of cells from human giant cell tumors of bone.

Authors:  S R Goldring; A L Schiller; H J Mankin; J M Dayer; S M Krane
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

4.  Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens.

Authors:  M A Horton; D Lewis; K McNulty; J A Pringle; T J Chambers
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Phenotypic characterization of the human fibrous histiocytoma giant cell tumor (GCT) cell line and its cytokine repertoire.

Authors:  J L Liesveld; S Rush; M C Kempski; A R Turner; J K Brennan; J C Gasson; C N Abboud
Journal:  Exp Hematol       Date:  1993-09       Impact factor: 3.084

6.  Monocyte-macrophage lineage of giant cell tumor of bone. Establishment of a multinucleated cell line.

Authors:  T S Huang; A D Green; C W Beattie; T K Das Gupta
Journal:  Cancer       Date:  1993-03-01       Impact factor: 6.860

7.  Establishment of a cell line from a human giant cell tumor of bone.

Authors:  M Kito; H Moriya; A Mikata; K Harigaya; T Takenouchi; N Takada; S Tatezaki; T Umeda
Journal:  Clin Orthop Relat Res       Date:  1993-09       Impact factor: 4.176

Review 8.  Type IV collagenases in invasive tumors.

Authors:  K Tryggvason; M Höyhtyä; C Pyke
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts.

Authors:  A M Delany; C E Brinckerhoff
Journal:  J Cell Biochem       Date:  1992-12       Impact factor: 4.429

10.  TNF-R55-specific form of human tumor necrosis factor-alpha induces collagenase gene expression by human skin fibroblasts.

Authors:  J Westermarck; L Häkkinen; W Fiers; V M Kähäri
Journal:  J Invest Dermatol       Date:  1995-08       Impact factor: 8.551

View more
  6 in total

1.  Analysis of mechanisms underlying BRMS1 suppression of metastasis.

Authors:  R S Samant; M J Seraj; M M Saunders; T S Sakamaki; L A Shevde; J F Harms; T O Leonard; S F Goldberg; L Budgeon; W J Meehan; C R Winter; N D Christensen; M F Verderame; H J Donahue; D R Welch
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

Review 3.  Modern interpretation of giant cell tumor of bone: predominantly osteoclastogenic stromal tumor.

Authors:  Yuhree Kim; Saqib Nizami; Hana Goto; Francis Y Lee
Journal:  Clin Orthop Surg       Date:  2012-05-17

4.  Matrix Metalloproteinase Activity in the Stromal Cell of Giant Cell Tumor of Bone.

Authors:  Alexander Rabinovich; Isabella W Y Mak; Robert W Cowan; Robert E Turcotte; Nigel Colterjohn; Gurmit Singh; Michelle Ghert
Journal:  Open Bone J       Date:  2009

5.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

6.  Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.

Authors:  Kenta Mukaihara; Yoshiyuki Suehara; Shinji Kohsaka; Keisuke Akaike; Yu Tanabe; Daisuke Kubota; Midori Ishii; Tsutomu Fujimura; Saiko Kazuno; Taketo Okubo; Tatsuya Takagi; Takashi Yao; Kazuo Kaneko; Tsuyoshi Saito
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.